CJC-1295 with DAC dosage: reported doses and schedule
An experimental long-acting peptide that triggers growth hormone release, with no proven muscle or recovery benefit.
Also called: CJC-1295 DAC, DAC:GRF, DAC-GRF.
GHRH analogues · Long-acting GHRH receptor agonist with an albumin-binding tag.
Typical reported dose: 1–2 mg total per week
- One trial injection: 30 mcg/kg: 30 mcg/kg once on day 0 once only, under the skin. Studied in a trial. Studied in: Healthy adults ages 21–61; research hormone-response study. (source)
- One trial injection: 60 mcg/kg: 60 mcg/kg once on day 0 once only, under the skin. Studied in a trial. Studied in: Healthy adults ages 21–61; research hormone-response study. (source)
- One trial injection: 125 mcg/kg: 125 mcg/kg once on day 0 once only, under the skin. Studied in a trial. Studied in: Healthy adults ages 21–61; research hormone-response study. (source)
- One trial injection: 250 mcg/kg: 250 mcg/kg once on day 0 once only, under the skin. Studied in a trial. Studied in: Healthy adults ages 21–61; research hormone-response study. (source)
- 30 mcg/kg every 14 days, two doses: 30 mcg/kg on days 0 and 14 once every 14 days, under the skin. Studied in a trial. Studied in: Healthy adults ages 21–61; five active recipients per arm. (source)
- 60 mcg/kg every 14 days, two doses: 60 mcg/kg on days 0 and 14 once every 14 days, under the skin. Studied in a trial. Studied in: Healthy adults ages 21–61; five active recipients per arm. (source)
Highest studied: Published weekly arm: 30 mcg/kg on days 0, 7 and 14; body weight is needed for an mg comparison..
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to CJC-1295 with DAC
- CJC-1295 without DAC: A peptide intended to trigger growth hormone release, with no human dosing study found.
- Tesamorelin: A peptide approved for deep abdominal fat in adults with HIV lipodystrophy.
- Sermorelin: An experimental short-acting peptide that triggers growth hormone release, with limited evidence of adult benefits.
- Ipamorelin: An experimental peptide that triggers growth hormone release.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Concerns regarding the public health risks associated with unapproved peptide products, Therapeutic Goods Administration and Chief Medical Officer · Therapeutic Goods Administration · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- EGRIFTA WR (tesamorelin) for injection, for subcutaneous use, U.S. Food and Drug Administration · FDA · 2025
- Supply unlicensed medicinal products (specials), MHRA · 2025
- December 4, 2024 Pharmacy Compounding Advisory Committee Meeting, FDA · 2024
- FDA Briefing Document Pharmacy Compounding Advisory Committee (PCAC) Meeting December 4, 2024, US Food and Drug Administration · 2024
- Anticoagulant medicines - Side effects, NHS
- DailyMed - GLUCOTROL XL- glipizide tablet, extended release, Pfizer Inc. · DailyMed
- Know When to Go to the ER, American College of Emergency Physicians · American College of Emergency Physicians
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.